FOURTH QUARTER (OCTOBER - DECEMBER 2024)
- Order intake SEK 305.0 M (317.7)
- Net sales SEK 322.7 (299.6)
- Operating profit SEK 73.6 M (44.4)
- Profit after tax SEK 60.0 M (31.5)
- Earnings per share before/after dilution SEK 1.75 (0.92)
- Cash flow from operating activities SEK 102.9 M (115.8)
- Order backlog SEK 1,813.2 M (1,864.4) at the end of the period.
TWELVE MONTHS (JANUARY – DECEMBER 2024)
- Order intake SEK 1,087.2 M (1,004.2)
- Net sales SEK 1,192.0 M (1,022.2)
- Operating profit SEK 260.5 M (114.9)
- Profit after tax SEK 203.5 M (81.6)
- Earnings per share before/after dilution SEK 5.94 (2.38)
- Cash flow from operating activities SEK 485.2 M (455.9)
- The Board of Directors proposes a dividend for the full-year 2024 of SEK 3.00 (0.70).
SIGNIFICANT EVENTS DURING THE FOURTH QUARTER
- GenesisCare UK has placed an order for RayStation.
- Number of radiotherapy clinics in China using RayStation now exceeds 100.
- Three centers in the French Unicancer network select RayStation.
- Institut Curie in France select RayStation for treatment planning with protons.
- RayStation is in clinical use for proton-arc therapy at Trento Proton Therapy Center in Italy.
SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD
- In January the Polish company Medim placed an order for the product DrugLog.
- In October 2024, Nina Grönberg was appointed new CFO for RaySearch Laboratories AB (publ), Nina took up her position January 27.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Johan Löf, CEO Tel: +46 8 510 530 00, e-mail: johan.lof@raysearchlabs.com
Nina Grönberg, CFO Tel: +46 8 510 530 00, e-mail: nina.gronberg@raysearchlabs.com
The information contained in this year-end report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication on February 21, 2025, at 7:45 a.m.
WEBCAST
CEO Johan Löf and CFO Nina Grönberg will present RaySearch’s year-end report for January-December 2024 at a webcast to be held in English on Friday, February 21, 2025 at 10:00-10:30 a.m. CET.
Link to webcast: RaySearch Year-end report 2024
About RaySearch
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems.
RaySearch software has been sold to over 1,000 clinics in 44 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. More information is available at raysearchlabs.com.
* Subject to regulatory clearance in some markets.